Abbott Stock Falls on Reduced Outlook and Guidance Cut

Abbott Laboratories reported Q1 2026 revenue of $11.2 billion, beating estimates by $160 million and growing 8% year-over-year, but simultaneously cut its full-year EPS guidance to $5.38–$5.58 from a prior range of $5.55–$5.80. The guidance reduction was primarily attributed to a mild flu season that dragged rapid and molecular diagnostics sales down 10%, as weaker-than-expected respiratory testing demand persisted into spring.

The guidance cut also reflects approximately $0.20 of EPS dilution from Abbott's $21–$23 billion acquisition of Exact Sciences, which closed March 23, 2026. The acquisition expands Abbott's oncology testing portfolio but adds near-term dilution at a time when diagnostics revenue is already under seasonal pressure. ABT fell 6% immediately following the announcement, underperforming sector peers.

Investors will be watching closely whether diagnostics demand normalizes in Q2 and how quickly Exact Sciences integration synergies materialize. Abbott's diversified model spanning medical devices, nutrition, established pharmaceuticals, and diagnostics provides a buffer against any single segment's weakness, and the company has historically recovered from weather-driven earnings disappointments. Near-term sentiment remains cautious given the quantitative ranking headwinds, but the organic revenue trajectory remains intact.

Related Stocks

• ABT